520 results on '"Denis, Cécile V."'
Search Results
52. Of von Willebrand factor and platelets
53. TaSER: Combining forces to stop the clot
54. Macrophage LRP1 contributes to the clearance of von Willebrand factor
55. Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
56. How to keep the factor VIII/von Willebrand factor complex in the circulation
57. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B
58. In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A
59. The Proteolytic Inactivation of Protein Z-Dependent Protease Inhibitor by Neutrophil Elastase Might Promote the Procoagulant Activity of Neutrophil Extracellular Traps in Sepsis
60. New Insight into Regulation of αIIbβ3 Integrin Signaling by Filamin A
61. von Willebrand disease: what does the future hold?
62. Anti-inflammatory Activity of the Protein Z-Dependent Protease Inhibitor
63. von Willebrand factor: at the crossroads of bleeding and thrombosis
64. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo
65. Altered thrombus formation in von Willebrand factor–deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa
66. The Proteolytic Inactivation of Protein Z-Dependent Protease Inhibitor by Neutrophil Elastase Might Promote the Procoagulant Activity of Neutrophil Extracellular Traps in Sepsis.
67. The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells
68. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
69. A compact integrated microfluidic oxygenator with high gas exchange efficiency and compatibility for long-lasting endothelialization
70. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3
71. Role of von Willebrand factor in tumor metastasis
72. Gain-of-Function Variant p.Pro2555Arg of von Willebrand Factor Increases Aggregate Size through Altering Stem Dynamics
73. Functional and clinical aspects of the anti-hemophilic bispecific antibody emicizumab
74. A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient
75. Molecular and Cellular Biology of von Willebrand Factor
76. VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells.
77. NAADP/SERCA3-Dependent Ca 2+ Stores Pathway Specifically Controls Early Autocrine ADP Secretion Potentiating Platelet Activation
78. A hemophilia A mouse model for the in vivo assessment of emicizumab function
79. Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells
80. A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A
81. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence
82. A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation
83. Von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate
84. A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
85. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen
86. P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Expressed on Platelets and Can Mediate Platelet-Endothelial Interactions In Vivo
87. Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
88. Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure
89. Localized reduction of atherosclerosis in von Willebrand factor–deficient mice
90. Aspects fonctionnels et cliniques de l'emicizumab, un anticorps bispécifique utilisé dans le traitement de l'hémophilie A.
91. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
92. Von Willebrand factor: how unique structural adaptations support and coordinate its complex function
93. Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
94. A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation
95. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets
96. VWF clearance: it’s glycomplicated
97. The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent
98. Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor
99. Pas de deux between VWF and ADAMTS13
100. Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.